Abstract
Introduction: We have previously reported that overexpression of visinin-like protein 1 (VSNL1) is frequently observed in advanced colorectal adenocarcinomas and correlates with poorer prognosis. In this study, we determined the levels of VSNL1 expression in the earlier stages of colorectal tumors including adenomas and adenocarcinomas, and attempted to clarify the functional significance of VSNL1 overexpression in colorectal carcinogenesis. Methods: Levels of VSNL expression in colorectal tumor tissues were analyzed using immunohistochemistry. The effects of VSNL1 downregulation and overexpression on cell proliferation, resistance to apoptosis, and invasiveness were determined using two VSNL1-overexpressing colorectal cancer cell lines, CW-2 and HCT-116 and VSNL1 inducibly expressing SNU-C5, respectively. Gene expression signatures in VSNL1-downregulated CW-2 and HCT-116 were identified using transcriptome and gene set enrichment analyses. Results: VSNL1 expression was restricted to only a few crypt cells in the non-tumorous epithelium, whereas it became enhanced in adenomas and adenocarcinomas with the progression of tumorigenesis. Downregulation of VSNL1 in CW-2 and HCT-116 cells suppressed their proliferation through induction of apoptosis. Conversely, overexpression of VSNL1 in SNU-C5 cells enhanced resistance to anoikis. Transcriptome and gene set enrichment analyses revealed that downregulation of VSNL1 altered the expression level of the apoptosis-related gene set in CW-2 and HCT-116 cells. Conclusion: VSNL1 plays a role in both the development and progression of colorectal tumors by enhancing cell viability.
Journal Section:
Research Article
References
1.
Hisabe
T
, Hirai
F
, Matsui
T
. Development and progression of colorectal cancer based on follow-up analysis
. Dig Endosc
. 2014 Apr
26
Suppl 2
73
7
.2.
Calderwood
AH
, Lasser
KE
, Roy
HK
. Colon adenoma features and their impact on risk of future advanced adenomas and colorectal cancer
. World J Gastrointest Oncol
. 2016 Dec 15
8
12
826
34
.3.
Kajimoto
Y
, Shirai
Y
, Mukai
H
, Kuno
T
, Tanaka
C
. Molecular cloning of two additional members of the neural visinin-like Ca(2+)-binding protein gene family
. J Neurochem
. 1993 Sep
61
3
1091
6
.4.
Lenz
SE
, Braunewell
KH
, Weise
C
, Nedlina-Chittka
A
, Gundelfinger
ED
. The neuronal EF-hand Ca(2+)-binding protein VILIP: interaction with cell membrane and actin-based cytoskeleton
. Biochem Biophys Res Commun
. 1996 Aug 23
225
3
1078
83
.5.
Mathisen
PM
, Johnson
JM
, Kawczak
JA
, Tuohy
VK
. Visinin-like protein (VILIP) is a neuron-specific calcium-dependent double-stranded RNA-binding protein
. J Biol Chem
. 1999 Oct 29
274
44
31571
6
.6.
Wickborn
C
, Klein-Szanto
AJ
, Schlag
PM
, Braunewell
KH
. Correlation of visinin-like-protein-1 expression with clinicopathological features in squamous cell carcinoma of the esophagus
. Mol Carcinog
. 2006 Aug
45
8
572
81
.7.
Xie
Y
, Chan
H
, Fan
J
, Chen
Y
, Young
J
, Li
W
et al. Involvement of visinin-like protein-1 (VSNL-1) in regulating proliferative and invasive properties of neuroblastoma
. Carcinogenesis
. 2007 Oct
28
10
2122
30
.8.
Fu
J
, Fong
K
, Bellacosa
A
, Ross
E
, Apostolou
S
, Bassi
DE
et al. VILIP-1 downregulation in non-small cell lung carcinomas: mechanisms and prediction of survival
. PLoS One
. 2008 Feb 27
3
2
e1698
.9.
Akagi
T
, Hijiya
N
, Inomata
M
, Shiraishi
N
, Moriyama
M
, Kitano
S
. Visinin-like protein-1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients
. Int J Cancer
. 2012 Sep 15
131
6
1307
17
.10.
Pitule
P
, Vycital
O
, Bruha
J
, Novak
P
, Hosek
P
, Treska
V
et al. Differential expression and prognostic role of selected genes in colorectal cancer patients
. Anticancer Res
. 2013 Nov
33
11
4855
65
.11.
He
C
, Liu
W
, Xiong
Y
, Wang
Y
, Pan
L
, Luo
L
et al. VSNL1 promotes cell proliferation, migration, and invasion in colorectal cancer by binding with COL10A1
. Ann Clin Lab Sci
. 2022 Jan
52
1
60
72
.12.
Korshunov
A
, Okonechnikov
K
, Sahm
F
, Ryzhova
M
, Stichel
D
, Schrimpf
D
et al. Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker
. Acta Neuropathol
. 2020 Mar
139
3
583
96
.13.
Dai
QQ
, Wang
YY
, Jiang
YP
, Li
L
, Wang
HJ
. VSNL1 promotes gastric cancer cell proliferation and migration by regulating P2X3/P2Y2 receptors and is a clinical indicator of poor prognosis in gastric cancer patients
. Gastroenterol Res Pract
. 2020
;2020
:7241942
.14.
Hijiya
N
, Miyawaki
M
, Kawahara
K
, Akamine
S
, Tsuji
K
, Kadota
J
et al. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma
. Hum Pathol
. 2008 Mar
39
3
316
23
.15.
McCarty
KS
Jr., Miller
LS
, Cox
EB
, Konrath
J
, McCarty
KS
. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies
. Arch Pathol Lab Med
. 1985 Aug
109
8
716
21
.16.
Kurogi
S
, Hijiya
N
, Hidano
S
, Sato
S
, Uchida
T
, Tsukamoto
Y
et al. Downregulation of ZNF395 drives progression of pancreatic ductal adenocarcinoma through enhancement of growth potential
. Pathobiology
. 2021
;88
(5
):374
–82
.17.
Hijiya
N
, Tsukamoto
Y
, Nakada
C
, Tung Nguyen
L
, Kai
T
, Matsuura
K
et al. Genomic loss of DUSP4 contributes to the progression of intraepithelial neoplasm of pancreas to invasive carcinoma
. Cancer Res
. 2016 May 1
76
9
2612
25
.18.
Ichimanda
M
, Hijiya
N
, Tsukamoto
Y
, Uchida
T
, Nakada
C
, Akagi
T
et al. Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas
. Cancer Sci
. 2018 Jan
109
1
250
8
.19.
Ohashi
T
, Idogawa
M
, Sasaki
Y
, Suzuki
H
, Tokino
T
. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis
. Mol Cancer Res
. 2013 Dec
11
12
1554
63
.20.
Yao
Y
, Wang
X
, Zhou
D
, Li
H
, Qian
H
, Zhang
J
et al. Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway
. Aging
. 2020 Jul 2
12
13
13059
75
.21.
Li
W
, Liu
C
, Huang
Z
, Shi
L
, Zhong
C
, Zhou
W
et al. AKR1B10 negatively regulates autophagy through reducing GAPDH upon glucose starvation in colon cancer
. J Cell Sci
. 2021 Apr 15
134
8
134
.22.
Ogawa
K
, Utsunomiya
T
, Mimori
K
, Tanaka
F
, Inoue
H
, Nagahara
H
et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer
. Clin Cancer Res
. 2005 Apr 15
11
8
2889
93
.23.
Tsai
WC
, Chao
YC
, Sheu
LF
, Chang
JL
, Nieh
S
, Jin
JS
. Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters
. Dis Markers
. 2007
;23
(3
):153
–60
.24.
Wu
ZY
, He
YQ
, Wang
TM
, Yang
DW
, Li
DH
, Deng
CM
et al. Glycogenes in oncofetal chondroitin sulfate biosynthesis are differently expressed and correlated with immune response in placenta and colorectal cancer
. Front Cell Dev Biol
. 2021
;9
:763875
.25.
Wu
Z
, Zhao
X
, Sun
Y
, Yu
H
. Curcumin suppresses colorectal cancer development with epithelial-mesenchymal transition via modulating circular RNA HN1/miR-302a-3p/PIK3R3 axis
. J Physiol Pharmacol
. 2022 Apr
73
2
). 26.
Yao
H
, Zhou
X
, Zhou
A
, Chen
J
, Chen
G
, Shi
X
et al. RFC5, regulated by circ_0038985/miR-3614-5p, functions as an oncogene in the progression of colorectal cancer
. Mol Carcinog
. 2023 Mar 29
62
6
771
85
.27.
Zhang
R
, Hu
M
, Chen
HN
, Wang
X
, Xia
Z
, Liu
Y
et al. Phenotypic heterogeneity analysis of APC-mutant colon cancer by proteomics and phosphoproteomics identifies RAI14 as a key prognostic determinant in east asians and westerners
. Mol Cell Proteomics
. 2023 Mar 18
22
5
100532
.28.
Infante
JR
, Somer
BG
, Park
JO
, Li
CP
, Scheulen
ME
, Kasubhai
SM
et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
. Eur J Cancer
. 2014 Aug
50
12
2072
81
.29.
Van Cutsem
E
, Hidalgo
M
, Canon
JL
, Macarulla
T
, Bazin
I
, Poddubskaya
E
et al. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
. Int J Cancer
. 2018 Oct 15
143
8
2053
64
.30.
Tolcher
AW
, Khan
K
, Ong
M
, Banerji
U
, Papadimitrakopoulou
V
, Gandara
DR
et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK
. Clin Cancer Res
. 2015 Feb 15
21
4
739
48
.31.
Chung
V
, McDonough
S
, Philip
PA
, Cardin
D
, Wang-Gillam
A
, Hui
L
et al. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial
. JAMA Oncol
. 2017 Apr 1
3
4
516
22
.32.
Huijberts
S
, van Geel
R
, van Brummelen
EMJ
, Opdam
FL
, Marchetti
S
, Steeghs
N
et al. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer
. Cancer Chemother Pharmacol
. 2020 May
85
5
917
30
.33.
van Geel
R
, van Brummelen
EMJ
, Eskens
F
, Huijberts
S
, de Vos
F
, Lolkema
M
et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
. Br J Cancer
. 2020 Apr
122
8
1166
74
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
